-
Something wrong with this record ?
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
M. Stork, S. Sevcikova, T. Jelinek, J. Minarik, J. Radocha, T. Pika, L. Pospisilova, I. Spicka, J. Straub, P. Pavlicek, A. Jungova, Z. Knechtova, V. Sandecka, V. Maisnar, R. Hajek, L. Pour
Status not-indexed Language English Country Switzerland
Document type Journal Article
NLK
Directory of Open Access Journals
from 2013
PubMed Central
from 2013
Europe PubMed Central
from 2013
ProQuest Central
from 2013-01-01
Open Access Digital Library
from 2013-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2013
- Publication type
- Journal Article MeSH
In multiple myeloma (MM), malignant plasma cells infiltrate the bone marrow. In some cases, plasma cells migrate out of the bone marrow creating either para-skeletal plasmacytomas (PS) or infiltrating soft tissues as extramedullary plasmacytomas (EMD). The aim of this study was to define risk groups in newly diagnosed MM (NDMM) patients with PS and EMD plasmacytomas. In total, 523 NDMM patients with PS plasmacytomas and 196 NDMM patients with EMD plasmacytomas were diagnosed in the Czech Republic between 2004 and 2021 using modern imaging methods. Patients' data were analyzed from the Registry of Monoclonal Gammopathies of the Czech Myeloma Group. In NDMM patients with PS plasmacytomas, we found a subgroup with <5% of bone-marrow plasma cells to have the best prognosis (mPFS: 58.3 months (95% CI: 33.0-NA); mOS: not reached). The subgroup with >5% of bone-marrow plasma cells and ≥3 plasmacytomas had the worst prognosis (mPFS: 19.3 months (95% CI: 13.4-28.8), p < 0.001; mOS: 27.9 months (95% CI: 19.3-67.8), p < 0.001). Our results show association between tumor burden and prognosis of NDMM patients with plasmacytomas. In the case of PS plasmacytomas, NDMM patients with low BM PC infiltration have an excellent prognosis.
Hematology and Oncology Department Charles University Hospital 323 00 Pilsen Czech Republic
Institute of Biostatistics and Analyses Ltd 625 00 Brno Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22031571
- 003
- CZ-PrNML
- 005
- 20230127131225.0
- 007
- ta
- 008
- 230119s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/biomedicines10102535 $2 doi
- 035 __
- $a (PubMed)36289797
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Stork, Martin $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic $1 https://orcid.org/0000000270728537
- 245 10
- $a Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas / $c M. Stork, S. Sevcikova, T. Jelinek, J. Minarik, J. Radocha, T. Pika, L. Pospisilova, I. Spicka, J. Straub, P. Pavlicek, A. Jungova, Z. Knechtova, V. Sandecka, V. Maisnar, R. Hajek, L. Pour
- 520 9_
- $a In multiple myeloma (MM), malignant plasma cells infiltrate the bone marrow. In some cases, plasma cells migrate out of the bone marrow creating either para-skeletal plasmacytomas (PS) or infiltrating soft tissues as extramedullary plasmacytomas (EMD). The aim of this study was to define risk groups in newly diagnosed MM (NDMM) patients with PS and EMD plasmacytomas. In total, 523 NDMM patients with PS plasmacytomas and 196 NDMM patients with EMD plasmacytomas were diagnosed in the Czech Republic between 2004 and 2021 using modern imaging methods. Patients' data were analyzed from the Registry of Monoclonal Gammopathies of the Czech Myeloma Group. In NDMM patients with PS plasmacytomas, we found a subgroup with <5% of bone-marrow plasma cells to have the best prognosis (mPFS: 58.3 months (95% CI: 33.0-NA); mOS: not reached). The subgroup with >5% of bone-marrow plasma cells and ≥3 plasmacytomas had the worst prognosis (mPFS: 19.3 months (95% CI: 13.4-28.8), p < 0.001; mOS: 27.9 months (95% CI: 19.3-67.8), p < 0.001). Our results show association between tumor burden and prognosis of NDMM patients with plasmacytomas. In the case of PS plasmacytomas, NDMM patients with low BM PC infiltration have an excellent prognosis.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Sevcikova, Sabina $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic $1 https://orcid.org/0000000271946771
- 700 1_
- $a Jelinek, Tomas $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, 708 00 Ostrava, Czech Republic $1 https://orcid.org/0000000254679253
- 700 1_
- $a Minarik, Jiri $u Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic $1 https://orcid.org/000000030513326X
- 700 1_
- $a Radocha, Jakub $u 4th Department of Medicine-Hematology, Charles University Hospital and Faculty of Medicine, 500 05 Hradec Kralove, Czech Republic
- 700 1_
- $a Pika, Tomas $u Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Pospisilova, Lenka $u Institute of Biostatistics and Analyses, Ltd., 625 00 Brno, Czech Republic $1 https://orcid.org/0000000345178200
- 700 1_
- $a Spicka, Ivan $u 1st Medical Department-Clinical Department of Hematology of the First Faculty of Medicine and General Teaching Hospital, Charles University, 128 08 Prague, Czech Republic
- 700 1_
- $a Straub, Jan $u 1st Medical Department-Clinical Department of Hematology of the First Faculty of Medicine and General Teaching Hospital, Charles University, 128 08 Prague, Czech Republic
- 700 1_
- $a Pavlicek, Petr $u Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, 100 34 Prague, Czech Republic
- 700 1_
- $a Jungova, Alexandra $u Hematology and Oncology Department, Charles University Hospital, 323 00 Pilsen, Czech Republic
- 700 1_
- $a Knechtova, Zdenka $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
- 700 1_
- $a Sandecka, Viera $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
- 700 1_
- $a Maisnar, Vladimir $u 4th Department of Medicine-Hematology, Charles University Hospital and Faculty of Medicine, 500 05 Hradec Kralove, Czech Republic
- 700 1_
- $a Hajek, Roman $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, 708 00 Ostrava, Czech Republic
- 700 1_
- $a Pour, Ludek $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
- 773 0_
- $w MED00205373 $t Biomedicines $x 2227-9059 $g Roč. 10, č. 10 (2022)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36289797 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230119 $b ABA008
- 991 __
- $a 20230127131217 $b ABA008
- 999 __
- $a ok $b bmc $g 1889553 $s 1182904
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2022 $b 10 $c 10 $e 20221011 $i 2227-9059 $m Biomedicines $n Biomedicines $x MED00205373
- LZP __
- $a Pubmed-20230119
